The Technion and the pharmaceutical company Pfizer have signed a cooperation agreement to speed up the implementation of scientific findings at the interface between artificial intelligence and drug development. The close cooperation was discussed during a visit to Israel by Pfizer CEO Dr. Albert Bourla and Dr. Mikael Dolsten, member of the Executive Board responsible for global research, together with the President of the Technion, Prof. Dr. Uri Sivan, Technion Vice Presidents and professors from the field of life sciences.
